Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J and Basilea End Ceftobiprole Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The news is, on the whole, good for Basilea, but questions remain on how the separation will actually work.

You may also be interested in...



CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms

Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry

CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms

Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry

Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up

Switzerland's Basilea licensed its Phase III anti-fungal isavuconazole to Japan's Astellas Pharma Feb. 24, just days after Johnson & Johnson revealed it was pulling out of its five-year deal with the biotech on the delayed antibiotic ceftobiprole

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel